Effective, durable options to address faltering dialysis access circuits have remained elusive, leaving a significant unmet need in long-term access maintenance. Until now. Promising interim data have emerged from the prospective, multicentre DEScover trial evaluating the Solaris DE sirolimus-eluting, electrospun polytetrafluoroethylene (PTFE) covered stent for the treatment of failed access circuits, drawing high hopes from leading global vascular specialists that a transformational solution might finally be at hand. “We have never had a drug-eluting platform that directly addressed the issue of edge restenosis, which is where most of these types of devices fail, when they fail,” says Peter Schneider (University of California San Francisco, San Francisco, USA). “This is where the Solaris DE platform will have a big impact—it will be a one-of-a-kind.”
The recently presented six-month results from DEScover demonstrated 95% overall target lesion primary patency (TLPP), including 100% patency in the arteriovenous graft (AVG) cohort and 91% patency in arteriovenous fistula (AVF) patients treated with Solaris DE, with no device‑related serious adverse events reported at 30 days. Here, Schneider and trial principal investigator Leonardo Harduin (State University of Rio de Janeiro, Rio de Janeiro, Brazil) discuss results from the DEScover clinical study, how this new technology might influence practice, as well as the data behind the device’s underlying Solaris SX covered stent.
This video is sponsored by Solaris.
